Literature DB >> 26846584

Preclinical lung disease in early rheumatoid arthritis.

Alejandro Robles-Perez1, Patricio Luburich2, Benigno Rodriguez-Sanchon3, Jordi Dorca4, Joan Miquel Nolla5, Maria Molina-Molina4, Javier Narvaez-Garcia5.   

Abstract

Early detection and treatment of lung disease in patients with rheumatoid arthritis (RA) may ameliorate disease progression. The objectives of this study were to investigate the frequency of asymptomatic lung abnormalities in early RA patients and the potential association of positive RA blood reactive biomolecules with lung involvement. A prospective observational study was performed in a cohort of patients with early RA (joint symptoms < 2 years) without respiratory symptoms, who were included in a screening program for lung disease with a baseline chest radiograph (CR) and complete pulmonary function tests (PFTs). In those patients with lung abnormalities on the CR or PFTs, a high-resolution chest computed tomography scan (HRCT) was performed. We included 40 patients (30 women). Altered PFTs were detected in 18 (45%) of these patients. These cases had a diffusion lung transfer capacity of carbon monoxide (DLCO) of <80% of predicted, without a significant reduction in the forced vital capacity. The HRCT detected abnormalities in 11 of the 18 patients. Diffuse bronchiectasis was the main finding. An inverse correlation between the anti-citrullinated peptide antibody (ACPA) levels and DLCO was found. Asymptomatic lung disease is present in up to 45% of early RA patients and can be determined by PFTs and ACPA levels.
© The Author(s) 2016.

Entities:  

Keywords:  Arthritis; autoantibodies; lung diseases; multidetector computed tomography; respiratory function tests; rheumatoid

Mesh:

Substances:

Year:  2016        PMID: 26846584      PMCID: PMC5720204          DOI: 10.1177/1479972315620746

Source DB:  PubMed          Journal:  Chron Respir Dis        ISSN: 1479-9723            Impact factor:   2.444


  26 in total

1.  Pulmonary involvement in early rheumatoid arthritis patients.

Authors:  Hisham M Habib; Ashraf A Eisa; Waleed R Arafat; Mohamed A Marie
Journal:  Clin Rheumatol       Date:  2010-05-26       Impact factor: 2.980

2.  Fleischner Society: glossary of terms for thoracic imaging.

Authors:  David M Hansell; Alexander A Bankier; Heber MacMahon; Theresa C McLoud; Nestor L Müller; Jacques Remy
Journal:  Radiology       Date:  2008-01-14       Impact factor: 11.105

3.  Citrullination in extra-articular manifestations of rheumatoid arthritis.

Authors:  T Bongartz; T Cantaert; S R Atkins; P Harle; J L Myers; C Turesson; J H Ryu; D Baeten; E L Matteson
Journal:  Rheumatology (Oxford)       Date:  2006-06-16       Impact factor: 7.580

Review 4.  The lung in rheumatoid arthritis.

Authors:  Anat Amital; David Shitrit; Yochai Adir
Journal:  Presse Med       Date:  2010-12-31       Impact factor: 1.228

5.  Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort.

Authors:  Gouri Koduri; Sam Norton; Adam Young; Nigel Cox; Paul Davies; Joe Devlin; Josh Dixey; Andrew Gough; Peter Prouse; John Winfield; Peter Williams
Journal:  Rheumatology (Oxford)       Date:  2010-03-11       Impact factor: 7.580

6.  Anti-citrullinated peptide antibodies in the serum of heavy smokers without rheumatoid arthritis. A differential effect of chronic obstructive pulmonary disease?

Authors:  Virginia Ruiz-Esquide; María José Gómara; Víctor I Peinado; José Alfredo Gómez Puerta; Joan Albert Barberá; Juan de Dios Cañete; Isabel Haro; Raimon Sanmartí
Journal:  Clin Rheumatol       Date:  2012-03-31       Impact factor: 2.980

7.  High resolution computed tomography of the lungs in patients with rheumatoid arthritis and interstitial lung disease.

Authors:  J McDonagh; M Greaves; A R Wright; C Heycock; J P Owen; C Kelly
Journal:  Br J Rheumatol       Date:  1994-02

8.  Prevalence of airway and parenchymal abnormalities in newly diagnosed rheumatoid arthritis.

Authors:  Margaret Wilsher; Louisa Voight; David Milne; Mark Teh; Nicola Good; John Kolbe; Megan Williams; Karen Pui; Tony Merriman; Karishma Sidhu; Nicola Dalbeth
Journal:  Respir Med       Date:  2012-07-13       Impact factor: 3.415

Review 9.  The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?

Authors:  Elizabeth Perry; Clive Kelly; Paul Eggleton; Anthony De Soyza; David Hutchinson
Journal:  Rheumatology (Oxford)       Date:  2014-05-15       Impact factor: 7.580

10.  Citrullination of fibronectin modulates synovial fibroblast behavior.

Authors:  Miriam A Shelef; David A Bennin; Deane F Mosher; Anna Huttenlocher
Journal:  Arthritis Res Ther       Date:  2012-11-05       Impact factor: 5.156

View more
  5 in total

Review 1.  Prevalence and risk factors of bronchiectasis in rheumatoid arthritis: A systematic review and meta-analysis.

Authors:  Lily W Martin; Lauren C Prisco; Weixing Huang; Gregory McDermott; Nancy A Shadick; Tracy J Doyle; Jeffrey A Sparks
Journal:  Semin Arthritis Rheum       Date:  2021-08-20       Impact factor: 5.431

Review 2.  Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.

Authors:  Yujie Dai; Weina Wang; Yikai Yu; Shaoxian Hu
Journal:  Clin Rheumatol       Date:  2020-08-13       Impact factor: 2.980

3.  Interstitial lung abnormalities in patients with early rheumatoid arthritis: A pilot study evaluating prevalence and progression.

Authors:  Huawei Dong; Peter J Julien; M Kristen Demoruelle; Kevin D Deane; Michael H Weisman
Journal:  Eur J Rheumatol       Date:  2018-10-01

Review 4.  Interstitial Lung Disease in Rheumatoid Arthritis Remains a Challenge for Clinicians.

Authors:  Elisabeth Bendstrup; Janne Møller; Sissel Kronborg-White; Thomas Skovhus Prior; Charlotte Hyldgaard
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

5.  A prospective study of lung disease in a cohort of early rheumatoid arthritis patients.

Authors:  A Robles-Pérez; P Luburich; S Bolivar; J Dorca; J M Nolla; M Molina-Molina; J Narváez
Journal:  Sci Rep       Date:  2020-09-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.